Azelastine HCl - CAS 79307-93-0
Catalog number: B0084-098591
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C22H25Cl2N3O
Molecular Weight:
418.36
COA:
Inquire
Targets:
Histamine Receptor
Description:
Azelastine HCl is a potent, second-generation, selective, histamine antagonist. It inhibits histamine via competing with histamine for the H1 receptor.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-098591 1 g $199 In stock
Bulk Inquiry
Publictions citing BOC Sciences Products
  • >> More
Brife Description:
histamine antagonist
Purity:
>98%
Synonyms:
ZELASTINE HYDROCHLORIDE; AC1Q1SYE; HYDROGEN AZELASTINE CHLORIDE; AKOS026749829; DR002552
MSDS:
Inquire
Application:
histamine antagonist
InChIKey:
YEJAJYAHJQIWNU-UHFFFAOYSA-N
InChI:
InChI=1S/C22H24ClN3O.ClH/c1-25-13-4-5-18(12-14-25)26-22(27)20-7-3-2-6-19(20)21(24-26)15-16-8-10-17(23)11-9-16;/h2-3,6-11,18H,4-5,12-15H2,1H3;1H
Canonical SMILES:
[H+].CN1CCCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl.[Cl-]
1.Lack of effect of azelastine and ketoconazole coadministration on electrocardiographic parameters in healthy volunteers.
Morganroth J1, Lyness WH, Perhach JL, Mather GG, Harr JE, Trager WF, Levy RH, Rosenberg A. J Clin Pharmacol. 1997 Nov;37(11):1065-72.
Azelastine, an antihistamine with additional pharmacologic properties, was evaluated for a possible influence on pharmacokinetic and electrocardiographic parameters due to its coadministration with CYP3A4 inhibitor ketoconazole (200 mg every 12 hrs). Twelve volunteers entered this three-period, open-label study. Electrocardiographic parameters (PR, QRS and QTc intervals and U-wave morphology) were monitored after 14 days of azelastine HCl (4.4 mg every 12 hrs), after 7 days of either azelastine/ketoconazole or azelastine/placebo, and after a 21-day washout period, which was then followed by a 7-day administration of ketoconazole alone. None of the treatments resulted in meaningful alterations of electrocardiographic variables. Pharmacokinetic parameters could not be estimated because ketoconazole metabolites interfered with azelastine assay procedures. In vitro tests with human liver microsomes were used to characterize azelastine's inhibition spectrum.
2.High performance liquid chromatographic determination of azelastine and desmethylazelastine in guinea pig plasma and lung tissue.
Langevin CN1, Pivonka J, Wichmann JK, Kucharczyk N, Sofia RD. Biomed Chromatogr. 1993 Jan-Feb;7(1):7-11.
Analytical methods have been developed for the simultaneous quantitation of azelastine (AZ) and desmethylazelastine (DAZ) in guinea pig plasma and lung tissue. The methods require a 1.00 mL plasma sample and a minimum 0.100 g lung sample. Both methods employ liquid/liquid organic extraction and back-extraction into dilute acid. Quantitation is performed by high performance liquid chromatography on a 2 x 250 mm 5 microns Hypersil CPS column using fluorescence detection. The linear quantitative ranges for AZ.HCl and DAZ.HBr in plasma are 0.156-160 ng/mL and 0.313-160 ng/mL, respectively. The linear quantitative ranges for AZ.HCl and DAZ.HBr in lung tissue are 0.039-20 micrograms/g for both.
3.Investigation on the efficacy and tolerance of azelastine (HCL) nasal spray versus ebastine tablets in patients with seasonal allergic rhinit
Conde Hernández J1, Palma Aguilar JL, Delgado Romero J. Allergol Immunopathol (Madr). 1995 Mar-Apr;23(2):51-7.
We compared the efficacy and tolerance of Azelastine nasal spray (0.14 mg in each nostril twice a day) versus Ebastine tablets (10 mg) as a single night dose in a Phase IV open, randomized, parallel-group clinical trial lasting 14 days, conducted with 63 patients diagnosed of seasonal allergic rhinitis. The symptoms assessed before and after the treatment period were: sneezing, nasal pruritus, rhinorrhea, nasal obstruction, conjunctival erythema, eye pruritus, eye watering, photophobia, pharyngeal pruritus and cough. Each symptom was rated by the patients according to a 4-point scale: absent: 0, mild: 1, moderate: 2, and severe: 3. The score required to be included in the study was 8 or above. In addition, the resistance of nasal fossae was assessed, before and after the treatment, by active anterior rhinomanometry, as well as the appearance of adverse events. Both drugs were equally effective both in the control of symptoms and in decreasing the airway resistance and no statistically significant differences were observed in the variables tested in both groups.
4.[The problem of recurrence of rhino-sinusal polyposis: pilot trial with locally administered azelastine HCL in the prevention of relapses].
Bussi M1, Carlevato MT, Majore L, Battaglio S, Napoli P, Cortesina G. Acta Otorhinolaryngol Ital. 1995 Apr;15(2):101-6.
Recurrent nasal polyposis is one of the most common unsolved problem in clinical rhinology. In the last few years a great number of histopathological, immunohistochemical and immunological studies on nasal polyps have been carried out by several Authors. Notwithstanding this, the aetiology of these formations still remains unknown. Many data suggest that the presence of polyps is the result of various inflammatory, allergic and pseudo-allergic processes which finally lead to the formation of the oedema constitutive of the polyp itself. In the present report a preliminary trial was carried out in order to evaluate the possibility of preventing recurrences by means of a locally administered anti-H1 receptors drug (Azelastine HCl). In the reported first phase of the study 10 allergic patients with bilateral polyposis were evaluated. Attention was given to the anti-edemigen activity of the drug, as well as to its influence on the local production of Secretory IgA, 7SIgA and albumines.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Histamine Receptor Products


CAS 362665-56-3 Tiprolisant

Tiprolisant
(CAS: 362665-56-3)

Tiprolisant is potent and selective nonimidazole inverse agonist at the histamine H3 receptor. (Ki=0.16 nM).

CAS 79307-93-0 Azelastine HCl

Azelastine HCl
(CAS: 79307-93-0)

Azelastine HCl is a potent, second-generation, selective, histamine antagonist. It inhibits histamine via competing with histamine for the H1 receptor.

LY-150310
(CAS: 103294-47-9)

LY-150310 is a histamine H1-receptor antagonist. It could alter prostanoid concentrations in vitro and in vivo.

CAS 980-71-2 Brompheniramine hydrogen maleate

Brompheniramine hydrogen maleate
(CAS: 980-71-2)

Brompheniramine hydrogen maleate is a histamine H1 receptors antagonist.

OUP16
(CAS: 1038917-11-1)

OUP16 is a potent and selective histamine H4 receptor(hH4R) agonist with 40-fold selectivity over the hH3R and superior to its (2S,5S)-configured optical antipo...

CAS 544707-19-9 JNJ10181457 dihydrochloride

JNJ10181457 dihydrochloride
(CAS: 544707-19-9)

JNJ10181457 dihydrochloride is a selective non-imidazole brain penetrant histamine H3 receptor antagonist with pKi values of 8.15 and 8.93 for rat and human H3 ...

CAS 1027330-97-7 A 943931

A 943931
(CAS: 1027330-97-7)

A 943931 is a potent and selective histamine H4 receptor antagonist.

Levoprotiline hydrochloride
(CAS: 76496-69-0)

Levoprotiline is a Histamine H1 receptor antagonist originated by Novartis. It is an antidepressant. But clinical trials for Major depressive disorder were disc...

CAS 1028327-66-3 VUF10460

VUF10460
(CAS: 1028327-66-3)

VUF10460 is a specific non-imidazole histamine H4 receptor agonist (pKi= 7.46, 8.22 for rat H4 receptor and human H4 receptor respectively) with 50-fold selecti...

CAS 195867-54-0 HTMT dimaleate

HTMT dimaleate
(CAS: 195867-54-0)

HTMT dimaleate is a histamine H1 and H2 receptor agonist with 4x104 fold activity over histamine in H2-mediated effects in natural suppressor cells. HTMT dimale...

CAS 153439-40-8 Fexofenadine HCl

Fexofenadine HCl
(CAS: 153439-40-8)

Fexofenadine inhibits histamine H1 receptor with IC50 of 246 nM.

CAS 398473-34-2 JNJ 5207852 dihydrochloride

JNJ 5207852 dihydrochloride
(CAS: 398473-34-2)

The hydrochloride salt form of JNJ 5207852, which has been found to be a histamine H3 receptor antagonist and could probably be used against obesity.

CAS 106243-16-7 Thioperamide

Thioperamide
(CAS: 106243-16-7)

Thioperamide is a potent histamine H3 and H4 antagonist/inverse agonist (Ki = 25 and 27 nM for human recombinant H3 and H4 receptors, respectively). Thioperamid...

CAS 145196-87-8 Iodophenpropit dihydrobromide

Iodophenpropit dihydrobromide
(CAS: 145196-87-8)

Iodophenpropit dihydrobromide is a selective and high affinity histamine H3 antagonist (KD = 0.3 nM).

CAS 147-24-0 Diphenhydramine HCl

Diphenhydramine HCl
(CAS: 147-24-0)

Diphenhydramine HCl (Benadryl), a histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a ...

CAS 3343-39-3 2-Pyridylethylamine dihydrochloride

2-Pyridylethylamine dihydrochloride
(CAS: 3343-39-3)

2-Pyridylethylamine dihydrochloride is a histamine H1 receptor agonist that produces vasoconstriction.

CAS 83881-52-1 Cetirizine diHCl

Cetirizine diHCl
(CAS: 83881-52-1)

Cetirizine is a major metabolite of hydroxyzine, and a racemic selective H1 receptor antagonist.

CAS 7456-24-8 Fonazine

Fonazine
(CAS: 7456-24-8)

Dimetotiazine is a histamine H1 receptor antagonist. It is a phenothiazine drug used for the treatment of migraine.

CAS 108498-50-6 FRG8701

FRG8701
(CAS: 108498-50-6)

FRG-8701 is a novel Histamine H2 receptor antagonist (IC50= 0.25~ 0.43 μM). FRG-8701 has relatively long-lasting antisecretory ef fects in comparison with famot...

CAS 3978-86-7 Azatadine dimaleate

Azatadine dimaleate
(CAS: 3978-86-7)

Azatadine is an histamine and cholinergic inhibitor with IC50 of 6.5 nM and 10 nM, respectively.

Chemical Structure

CAS 79307-93-0 Azelastine HCl

Quick Inquiry

Verification code

Featured Items